All articles by Staff Writer
Staff Writer
Greenway and Luma team up on patient engagement solution
Greenway Patient Connect aims to support three daily elements of a patient’s experience – access, communication, and readiness.
GE HealthCare and Biofourmis partner to enhance post-hospital care
Biofourmis’ care-at-home solutions include wearable devices, digital platforms, and in-home services orchestration technology.
On-Device AI Healthcare Company Noul Becomes First Korean Diagnostic Company to Join Swiss Malaria Group
Noul Co., Ltd., (376930.KR), an On-Device AI healthcare company, announced that its European subsidiary (noul GmbH) has become an official member of the Swiss Malaria Group, a Swiss public, private, academic & civil society leadership network for a malaria-free world.
MEDICA and COMPAMED: Medical technology business is profiting from strong appeal to international visitors
High proportion of decision-makers, unique variety of innovations and a high-calibre accompanying programme
COMPAMED 2023, between the poles of top innovation and regulation
The med-tech supply sector shows off its “high-performance mode”
Thermo Fisher Scientific to Acquire CorEvitas
Thermo Fisher Scientific Inc. (NYSE: TMO) (“Thermo Fisher”), the world leader in serving science, today announced it has entered into a definitive agreement to acquire CorEvitas, LLC (“CorEvitas”), a leading provider of regulatory-grade, real-world evidence for approved medical treatments and therapies, from Audax Private Equity (“Audax”), for $912.5 million in cash.
Annual Congress 2023 of the European Academy of Allergy and Clinical Immunology: Study Shows Promising Results for Immunotherapy Targeting Skin Cancer
A ground-breaking study was presented 10 June at the Hybrid Congress in Hamburg organized by the European Academy of Allergy & Clinical Immunology (EAACI). Study was conducted by researchers from King’s College London and Guy’s and St Thomas’ NHS Foundation Trust has revealed promising results for a new class of immunotherapy in the fight against aggressive skin cancer. The study investigates the efficacy of a novel antibody in targeting and treating melanomas, demonstrating its ability to activate the immune response and impede melanoma growth in mice.
Africa Health ExCon-2023: The Egyptian Authority for Unified Procurement (UPA) and the Arab Hospital Federation (AHF) signed a protocol on cooperation to consolidate the role of the Africa Health ExCon
The Egyptian Authority for Unified Procurement (UPA) and Arab Hospital Federation (AHF) on Tuesday signed a Protocol of Cooperation to enhance the role of the Africa Health ExCon-2023 in its second edition under the title ”Your gateway to Health and Innovation in Africa”. The Africa Health ExCon Exhibition is held under the patronage of His Excellency the Egyptian President Abdel Fattah El-Sisi. In addition, it will take place between the 7th and the 10th of June 2023 at the Egypt International Exhibition center in Cairo, Egypt.
Toronto Airport Authority Partners with Kraken Sense, a Leading Canadian Tech Company, as Part of Study to Combat COVID-19
TORONTO–(BUSINESS WIRE)–The Greater Toronto Airports Authority (GTAA) is partnering with Kraken Sense, a leader in real-time pathogen detection devices, as part of a study funded in part by the National Research Council of Canada Industrial Research Assistance Program (NRC IRAP) to conduct tests on airport wastewater for Monkeypox and Omicron, a variant of SARS-CoV-2, the virus that causes COVID-19. Kraken Sense is testing multiple samples of wastewater at Toronto Pearson Airport using their technology to obtain quantitative results in under an hour without sacrificing the accuracy of results in contrast to traditional PCR technology, which can take multiple days to turnaround.
Ellipses Pharma Announces FDA Approval of IND Application for EP0042 for Patients With Acute Myeloid Leukaemia
LONDON–(BUSINESS WIRE)–Ellipses Pharma (“Ellipses”), a global drug development company focused on accelerating the development of cancer medicines and treatments through an innovative drug development model, today announces that the U.S. Food and Drug Administration (FDA) has cleared the company’s Investigational New Drug (IND) application for EP0042, a dual FLT-3 and Aurora kinase inhibitor.